Antitumor activity of multi-kinase inhibitors in colorectal cancer
View Patent ↗A composition for use in the prevention and/or treatment of colorectal cancer in a patient, comprising: a) a compound of Formula (I), where R 1 , R 2 , and R 3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof; R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are, each one and independently, hydrogen, hydroxyl or an —OR 4 group, where R 4 is a protector group according to the previous definition; and b) at least one chemotherapeutic agent.
1. A method of treating colorectal cancer in a patient, said method comprising administering to a patient suffering from colorectal cancer, (a) a compound of Formula (III) or a salt, co-crystal or solvate thereof, and (b) at least one chemotherapeutic agent, or a salt, co-crystal or solvate thereof,
wherein a molar ratio of the compound of Formula (III) or salt, co-crystal or solvate thereof to the at least one chemotherapeutic agent or salt, co-crystal or solvate thereof is from 1:10 to 1:36,
wherein the compound of Formula (III) or salt, co-crystal or solvate thereof and said at least one chemotherapeutic agent, or salt, co-crystal or solvate thereof are administered simultaneously, sequentially or at independent times from each other, to said patient, and
wherein said chemotherapeutic agent comprises 5-fluorouracil.
2. The method of claim 1 , wherein the patient is suffering from primary colorectal cancer.
3. The method of claim 1 , wherein the patient is suffering from primary colorectal adenocarcinoma.
4. The method of claim 1 , wherein the compound of Formula (III) or a salt, co-crystal or solvate thereof, and the at least one chemotherapeutic agent or a salt, co-crystal or solvate thereof are combined to form a composition.
5. The method of claim 4 , wherein the composition further comprises at least one pharmaceutical excipient and/or carrier.